Clinical Trials on Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder

Total 1872 results

Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder

EBV-Related Post-Transplant Lymphoproliferative Disorder | Monomorphic Post-Transplant Lymphoproliferative Disorder | Polymorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder | Recurrent Polymorphic Post-Transplant Lymphoproliferative... and other conditions

United States
University of Washington

Recruiting

Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies

Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Refractory Mantle Cell Lymphoma | Recurrent Follicular... and other conditions

United States
Timothy Voorhees

Recruiting

Tafasitamab and Rituximab for Front-Line Treatment of Post-Transplant Lymphoproliferative Disorder

Polymorphic Post-Transplant Lymphoproliferative Disorder | Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder

United States
A.O. Ospedale Papa Giovanni XXIII

Completed

Fludarabine, Cyclophosphamide, Doxorubicin and Rituximab for the Treatment of Post-transplant Lymphoproliferative Disease (PTLD) (FCD-R)

Post-transplant Lymphoproliferative Disease (PTLD) | Non Burkitt

Italy
National Institute of Allergy and Infectious Diseases...
Clinical Trials in Organ Transplantation in Children

Completed

Biomarkers for Post-Transplant Lymphoproliferative Disorders in Children

Liver Transplant | Kidney Transplant | Heart Transplant | EBV-Related PTLD | Small Intestine Transplant | PTLDs

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Terminated

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

Lymphoproliferative Disorder

United States
University Hospital, Basel, Switzerland

Not yet recruiting

EBV-Tscm Cytotoxic T Cells (CTLs) for EBV- Driven Lymphomas/ Diseases (ESPECT)

EBV Lymphoma | Post-transplant Lymphoproliferative Disease (PTLD)

Switzerland
Deepa Jagadeesh

Terminated

Rituximab and Acalabrutinib in Newly Diagnosed B Cell Post Transplant Lymphoproliferative Disorder

Post-transplant Lymphoproliferative Disorder

United States
Dr. Jean-Sebastien Delisle, MD, PhD

Recruiting

A Study of the Safety and Efficacy of EBV Specific T-cell Lines (EBV-TCL-01)

Lymphoma | Epstein-Barr Virus Infections | Post-Transplant Lymphoproliferative Disorder

Canada
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH

Completed

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy (PTLD-2)

Posttransplant Lymphoproliferative Disorder

Germany
Masonic Cancer Center, University of Minnesota
Millennium Pharmaceuticals, Inc.

Terminated

Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

Lymphoproliferative Disorder

United States
Case Comprehensive Cancer Center
Genentech, Inc.

Withdrawn

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder | PTLD
Washington University School of Medicine

Recruiting

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder

United States
Atara Biotherapeutics

Recruiting

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE)

Lymphoproliferative Disorders | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Allogeneic Hematopoietic Cell Transplant | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD)

United States, Austria, Australia, Belgium, Canada, France, Italy, Spain, United Kingdom
National Institute of Diabetes and Digestive and...

Completed

Detection and Cytotoxic T Lymphocyte Therapy of Post-Transplant Lymphoproliferative Disorder After Liver Transplant

Lymphoproliferative Disorders | Liver Disease

United States
University College, London
bluebird bio

Active, not recruiting

Immunotherapy With Tacrolimus Resistant EBV CTL for Lymphoproliferative Disease After Solid Organ Transplant (ITREC)

Post-transplant Lymphoproliferative Disease | Transplant-Related Hematologic Malignancy

United Kingdom
Baylor College of Medicine
National Cancer Institute (NCI)

Completed

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies (DA-EPOCH-R)

Diffuse Large B Cell Lymphoma | Post Transplant Lymphoproliferative Disorder | Primary Mediastinal (Thymic) Large B-cell Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
Massachusetts General Hospital
Dana-Farber Cancer Institute; Beth Israel Deaconess Medical Center; Brigham and... and other collaborators

Completed

Bortezomib Plus Rituximab for EBV+ PTLD

Epstein Barr Virus Infections | Post-transplant Lymphoproliferative Disease | Solid Organ Transplant | Stem Cell Transplant (Bone Marrow Transplant)

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Terminated

High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Post-Transplant Lymphoproliferative Disorder | Recurrent Burkitt Lymphoma | Refractory Burkitt Lymphoma

United States
University Health Network, Toronto

Recruiting

Ex-vivo Delivery of Rituximab to Prevent PTLD in EBV Mismatch Lung Transplant Recipients: A Pilot Trial

Epstein-Barr Virus Infections | Post-transplant Lymphoproliferative Disorder

Canada
Cell Medica Ltd

Terminated

Cellular Immunotherapy for Viral Induced Cancer - EBV Positive Lymphomas (CIVIC)

Lymphoma, Large B-Cell, Diffuse | Hodgkin Lymphoma | Post-transplant Lymphoproliferative Disorder

United States
University of Miami

Terminated

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

Epstein Barr Virus Associated Non Hodgkin's Lymphoma | Epstein Barr Virus Associated Hodgkin's Lymphoma | Post-Transplant Lymphoproliferative Disease

United States
Atara Biotherapeutics

Recruiting

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Lymphoproliferative Disorders | Leiomyosarcoma | Stem Cell Transplant Complications | Solid Organ Transplant Complications | Epstein-Barr Virus (EBV)-Associated Diseases | EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD) | Allogeneic Hematopoietic Cell Transplant | EBV+ Sarcomas | EBV+ Lymphoproliferative... and other conditions

United States, Austria, Belgium, France, Italy, Spain, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders

Recurrent Lymphoproliferative Disorder | Refractory Lymphoproliferative Disorder

United States
University Hospital, Strasbourg, France

Recruiting

Evaluation of the Efficacy of a Treatment by One Single Dose of Rituximab (375mg/m2 ) in the Prevention of the Epstein Barr Virus (EBV) Primary Infection and Post-transplant Lymphoproliferative Disorder in Adult EBV Seronegative Patients Who Received an EBV Seropositive Kidney Allograft (REPLY)

Epstein-Barr Virus Infections

France
University of Oslo School of Pharmacy
Oslo University Hospital

Completed

Insulin Secretion and Advagraf (ADVA-09)

Post Transplant Diabetes Mellitus

Norway
Victor Aquino

Temporarily not available

Treatment Use of the CliniMACS® CD34 TCR Alpha/Beta for Allogenic Transplant (Expanded Access Use)

Transplant-Related Disorder | GVH - Graft Versus Host Reaction

United States
Charite University, Berlin, Germany

Terminated

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Post-transplantation Lymphoproliferative Disorder

Australia, France, Germany, Sweden
M.D. Anderson Cancer Center
Pfizer

Not yet recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
Mayo Clinic

Completed

Intensive Glycemic Management and Outcomes Following Liver Transplantation

Hospital Hyperglycemia | Post-transplant Hyperglycemia

United States
Boston Children's Hospital
United States Department of Defense; Stanford University

Active, not recruiting

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score (TEAMMATE)

Chronic Kidney Diseases | Post-transplant Lymphoproliferative Disorder | Immunosuppression | Pediatric Heart Transplantation | Cardiac Allograft Vasculopathy | Heart Transplant Failure and Rejection | Heart Transplant Infection

United States
University of Aarhus
Odense University Hospital; Aarhus University Hospital; Rikshospitalet University...

Recruiting

EVITA Study - Epstein-Barr Virus Infection moniToring in renAl Transplant Recipients (EVITA)

Post-transplant Lymphoproliferative Disorder | EBV Infection | EBV Viremia | Epstein-Barr Virus Associated Lymphoproliferative Disorder

Denmark, Norway
Children's Healthcare of Atlanta

Terminated

Relationship Between EBV and PTLD

Pediatric Heart Transplant

United States
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Adult Patients Using a daGOAT Model

Transplant-Related Disorder

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT Model

Transplant-Related Disorder

China
Stanford University
Novartis

Completed

Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host Disease

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell, Peripheral | Bone Marrow Transplant Failure

United States, Canada
Gruppo Italiano Studio Linfomi

Completed

Bendamustine and Rituximab As Salvage Therapy In Patients With Chronic Lymphoproliferative Disorders

Relapsed or Refractory Chronic Lymphoproliferative Disorders

Italy
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
Theriva Biologics, Inc.
Washington University School of Medicine

Recruiting

SYN-004 Safety and Tolerability in Allo-HCT Subjects

121121000119106, Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder)

United States
Hospices Civils de Lyon

Completed

aCGH Impacts Survival in Plasma Cell PTLD

Post-transplantation Lymphoproliferative Disorders

France
University Medical Center Groningen
Dutch Kidney Foundation; Innovation Fund of the Dutch Medical Insurance Companies

Completed

ACtive Care After Transplantation, the ACT Study (ACT)

Metabolic Syndrome | Kidney Transplant | Post-transplant Weight Gain

Netherlands
Vancouver General Hospital

Terminated

Insulin Therapy for Post-transplant Glucocorticoid Induced Hyperglycemia (PTHG)

Post-Transplant Glucocorticoid Induced Diabetes

Canada
St. Petersburg State Pavlov Medical University

Active, not recruiting

PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT (PTCyRuxo)

Acute Myeloid Leukemia | Acute Lymphoid Leukemia | Stem Cell Transplant Complications | Graft-versus-host-disease

Russian Federation
Samsung Medical Center
Medipost Co Ltd.

Unknown

Umbilical Cord Blood-derived Mesenchymal Stem Cells for the Treatment of Steroid-refractory Acute or Chronic Graft-versus-host-disease (GVHD-MSC)

Graft-Versus-Host Disease | GVHD | Disorder Related to Transplantation | Allogeneic Hematopoietic Transplant

Korea, Republic of
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
Memorial Sloan Kettering Cancer Center
Pharmacyclics LLC.; Janssen Biotech, Inc.

Recruiting

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL) | Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)

United States
University Health Network, Toronto

Completed

Decidual Stromal Cells to Treat Graft-vs-Host Disease After Stem Cell Transplant for Myelodysplastic Syndrome/Myeloproliferative Neoplasm (DSC-SR)

Myelodysplastic/Myeloproliferative Neoplasm | Allogeneic Hematopoietic Cell Transplant | Steroid Refractory GVHD

Canada
Oslo University Hospital

Completed

Home Care in Allogeneic Haematopoietic Stem Cell Transplantation

Quality of Life | Stem Cell Transplant Complications | GVH - Graft Versus Host Reaction

Norway
Oslo University Hospital

Completed

GLP-1 Effects on Insulin and Glucagon in PTDM

Post-transplant Diabetes Mellitus

Norway

Clinical Trials on Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations